2023
NCCN Guidelines® Insights: Cervical Cancer, Version 1.2024.
Abu-Rustum N, Yashar C, Arend R, Barber E, Bradley K, Brooks R, Campos S, Chino J, Chon H, Crispens M, Damast S, Fisher C, Frederick P, Gaffney D, Gaillard S, Giuntoli R, Glaser S, Holmes J, Howitt B, Lea J, Mantia-Smaldone G, Mariani A, Mutch D, Nagel C, Nekhlyudov L, Podoll M, Rodabaugh K, Salani R, Schorge J, Siedel J, Sisodia R, Soliman P, Ueda S, Urban R, Wyse E, McMillian N, Aggarwal S, Espinosa S. NCCN Guidelines® Insights: Cervical Cancer, Version 1.2024. Journal Of The National Comprehensive Cancer Network 2023, 21: 1224-1233. PMID: 38081139, DOI: 10.6004/jnccn.2023.0062.Peer-Reviewed Original ResearchConceptsCervical cancerNCCN guidelinesNCCN Guidelines InsightsSystemic therapy recommendationsAdvanced cervical cancerMetastatic diseaseTreatment landscapeClinical outcomesDiagnostic workupHistopathologic classificationTherapy recommendationsCancerMolecular profileAspects of managementRecent updatesDiagnostic featuresGuidelinesWorkupStagingDiseaseRecurrentPathologyInvestigating the Relationship between the Dose to the Recto-Vaginal Reference Point and Vaginal Stenosis among Cervical Cancer Patients Treated at a North American Academic Institution
Adefres B, Wallington D, Tien C, Damast S. Investigating the Relationship between the Dose to the Recto-Vaginal Reference Point and Vaginal Stenosis among Cervical Cancer Patients Treated at a North American Academic Institution. International Journal Of Radiation Oncology • Biology • Physics 2023, 117: e501. DOI: 10.1016/j.ijrobp.2023.06.1746.Peer-Reviewed Original ResearchVaginal stenosisDose constraintsMedian doseMultivariable Cox proportional hazards regressionCox proportional hazards regressionCohort median ageAdvanced cervical cancerInterstitial needlesKaplan-Meier methodCervical cancer patientsProportional hazards regressionLog-rank testHR-CTV D90MATERIAL/METHODSImage-guided brachytherapyNorth American academic institutionsLACC patientsPrimary endpointCumulative incidenceOnly patientsPatient demographicsMedian ageCervical cancerCancer patientsSingle institution
2022
Brachytherapy impacts on sexual function: An integrative review of the literature focusing on cervical cancer
Chin C, Damast S. Brachytherapy impacts on sexual function: An integrative review of the literature focusing on cervical cancer. Brachytherapy 2022, 22: 30-46. PMID: 36567175, DOI: 10.1016/j.brachy.2022.10.012.Peer-Reviewed Original ResearchConceptsSexual morbidityCervical cancerSexual sequelaeImage-guided adaptive brachytherapyQuality of lifeSecondary preventionCurative treatmentDosimetric factorsCommon symptomsVaginal doseCancer patientsClose surveillanceSexual functionIndirect sequelaeSexual symptomsVaginal morbidityVaginal toxicitySexual dysfunctionAdaptive brachytherapySexual healthClinical interventionsMorbidityCritical organsSequelaeEffect relationshipSingle application hybrid interstitial brachytherapy for cervical cancer: an institutional approach during the COVID-19 pandemic
Damast S, Tien CJ, Young M, Altwerger G, Ratner E. Single application hybrid interstitial brachytherapy for cervical cancer: an institutional approach during the COVID-19 pandemic. Journal Of Contemporary Brachytherapy 2022, 14: 66-71. PMID: 35233237, PMCID: PMC8867238, DOI: 10.5114/jcb.2022.113058.Peer-Reviewed Original ResearchOverall treatment timeHR-CTV DCervical cancerMucosal toxicityMedian high-risk clinical target volumeHigh-risk clinical target volumeCOVID-19 pandemicLocal control outcomesPre-COVID cohortClinical target volumeMagnetic resonance imagingGastrointestinal eventsRetrospective reviewCC patientsEarly outcomesCOVID groupMedian numberInpatient resourcesInterstitial brachytherapyGrade 2Local controlResonance imagingSeparate weeksTarget volumePatients
2021
Reports From Four International Clinical Trials for Cancers of the Cervix, Uterus and Vulva, and a New Guideline for Cervical Cancer
Damast S, Fields E, Kidd E, Harkenrider M, Chopra S, Chino J. Reports From Four International Clinical Trials for Cancers of the Cervix, Uterus and Vulva, and a New Guideline for Cervical Cancer. International Journal Of Radiation Oncology • Biology • Physics 2021, 111: 299-306. PMID: 34473967, DOI: 10.1016/j.ijrobp.2021.05.002.Peer-Reviewed Original Research
2020
NCCN Guidelines Insights: Cervical Cancer, Version 1.2020.
Abu-Rustum NR, Yashar CM, Bean S, Bradley K, Campos SM, Chon HS, Chu C, Cohn D, Crispens MA, Damast S, Fisher CM, Frederick P, Gaffney DK, Giuntoli R, Han E, Huh WK, Lurain Iii JR, Mariani A, Mutch D, Nagel C, Nekhlyudov L, Fader AN, Remmenga SW, Reynolds RK, Sisodia R, Tillmanns T, Ueda S, Urban R, Wyse E, McMillian NR, Motter AD. NCCN Guidelines Insights: Cervical Cancer, Version 1.2020. Journal Of The National Comprehensive Cancer Network 2020, 18: 660-666. PMID: 32502976, DOI: 10.6004/jnccn.2020.0027.Peer-Reviewed Original ResearchConceptsCervical cancerNCCN Guidelines InsightsSystemic therapy recommendationsTreatment of patientsHistopathologic classification systemNCCN guidelinesMetastatic diseaseDiagnostic workupEndocervical adenocarcinomaTherapy recommendationsPatientsCancerDiseaseRecent updatesClassification systemGuidelinesHPVAdenocarcinomaWorkupStagingRecurrent
2019
Cervical Cancer, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology.
Koh WJ, Abu-Rustum NR, Bean S, Bradley K, Campos SM, Cho KR, Chon HS, Chu C, Clark R, Cohn D, Crispens MA, Damast S, Dorigo O, Eifel PJ, Fisher CM, Frederick P, Gaffney DK, Han E, Huh WK, Lurain JR, Mariani A, Mutch D, Nagel C, Nekhlyudov L, Fader AN, Remmenga SW, Reynolds RK, Tillmanns T, Ueda S, Wyse E, Yashar CM, McMillian NR, Scavone JL. Cervical Cancer, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology. Journal Of The National Comprehensive Cancer Network 2019, 17: 64-84. PMID: 30659131, DOI: 10.6004/jnccn.2019.0001.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic Combined Chemotherapy ProtocolsBrachytherapyCervix UteriChemoradiotherapy, AdjuvantFemaleFertility PreservationHumansHysterectomyMass ScreeningMedical OncologyNeoplasm StagingOrgan Sparing TreatmentsPapanicolaou TestPapillomaviridaePapillomavirus InfectionsSocieties, MedicalUnited StatesUterine Cervical NeoplasmsConceptsCervical cancerHuman papilloma virus vaccinationNCCN Clinical Practice GuidelinesTreatment of recurrentAdvanced cervical cancerClinical practice guidelinesMalignant epithelial tumorsNCCN guidelinesMetastatic diseaseVirus vaccinationUterine cervixCommon cancerPrecancerous lesionsFull guidelinePractice guidelinesEpithelial tumorsRoutine screeningCancerScreening protocolTreatmentGuidelinesMost casesEarly stagesCervixVaccination
2015
Factors Predictive of Improved Survival in Patients With Brain Metastases From Gynecologic Cancer
Gressel GM, Lundsberg LS, Altwerger G, Katchi T, Azodi M, Schwartz PE, Ratner ES, Damast S. Factors Predictive of Improved Survival in Patients With Brain Metastases From Gynecologic Cancer. International Journal Of Gynecological Cancer 2015, 25: 1711-1716. PMID: 26332394, PMCID: PMC4623851, DOI: 10.1097/igc.0000000000000554.Peer-Reviewed Original ResearchConceptsBrain metastatic diseaseEpithelial ovarian cancerBrain metastasesEndometrial cancerCervical cancerGynecologic cancerSurgical resectionTwo-year overall survival ratesLargest single-institution experienceSingle institution experienceOverall survival rateOverall survival dataMedian survival timeSignificant hazard ratioLong-term survivalHazard ratioMetastatic diseaseOverall survivalImproved survivalRetrospective reviewIntracranial metastasesPalliative carePoor prognosisCancer increasesFactors Predictive